Article Versions Notes

Irelli A, Parisi A, D’Orazio C, Sidoni T, Rotondaro S, Patruno L, Pavese F, Bafile A, Resta V, Pizzorno L, et al. Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. Cancers. 2022; 14(12):3003. https://doi.org/10.3390/cancers14123003

Irelli, Azzurra, Alessandro Parisi, Carla D’Orazio, Tina Sidoni, Silvia Rotondaro, Leonardo Patruno, Francesco Pavese, Alberto Bafile, Valter Resta, Laura Pizzorno, and et al. 2022. "Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status" Cancers 14, no. 12: 3003. https://doi.org/10.3390/cancers14123003

Irelli, A., Parisi, A., D’Orazio, C., Sidoni, T., Rotondaro, S., Patruno, L., Pavese, F., Bafile, A., Resta, V., Pizzorno, L., Ciuffetelli, V., Dal Mas, A., Calvisi, G., Di Sibio, A., Marzullo, A., Zelli, V., Compagnoni, C., Tessitore, A., Alesse, E., ... Cannita, K. (2022). Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. Cancers, 14(12), 3003. https://doi.org/10.3390/cancers14123003